查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1668041

格林-巴利綜合症診斷市場 - 全球產業規模、佔有率、趨勢、機會和預測，按測試、最終用途、地區和競爭細分，2020-2030 年預測

Guillain-Barre Syndrome Diagnostics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test, By End-use, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 187 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球格林巴利症候群診斷市場價值為 1.5095 億美元，預計到 2030 年將達到 1.7342 億美元，預測期內複合年成長率為 5.12%。格林巴利症候群 (GBS) 是一種罕見但嚴重的神經系統疾病，人體的免疫系統錯誤地攻擊周邊神經系統，導致肌肉無力、麻木，嚴重時甚至會導致癱瘓。早期準確的診斷對於有效的管理和治療至關重要，但該疾病的多變性和與其他神經系統疾病的重疊症狀使其識別具有挑戰性。

市場概況
預測期 2026-2030
2024 年市場規模 1.5095 億美元
2030 年市場規模 1.7342億美元
2025-2030 年複合年成長率 2.30％
成長最快的領域 腰椎穿刺
最大的市場 北美洲

診斷格林巴利症候群的第一步是進行詳細的臨床檢查和了解病史。醫生會評估肌肉無力的發生和發展情況，通常從下肢開始，然後向上身發展。反射通常會減弱或消失，這是格林-巴利症候群的顯著特徵。患者也可能報告感覺障礙，例如刺痛或疼痛，以及自主神經功能障礙，包括血壓波動和心律不整。由於格林-巴利症候群常常由先前的感染引發，因此醫生會詢問近期的疾病，例如呼吸道感染或胃腸道疾病。

神經傳導研究（NCS）和肌電圖（EMG）是確認GBS的重要診斷工具。 NCS 測量周邊神經中電訊號的速度和強度。在格林-巴利症候群中，這些訊號會因神經脫髓鞘或軸突損傷而減慢或受阻。 EMG 可以評估肌肉對神經刺激的反應，有助於區分 GBS 與其他神經肌肉疾病。這些測試的結果為 GBS 的亞型提供了寶貴的見解，例如急性發炎性脫髓鞘多發性神經病變 (AIDP) 或急性運動軸突性神經病變 (AMAN)。

通常會進行腰椎穿刺（脊椎穿刺）來分析包圍大腦和脊髓的腦脊髓液（CSF）。在格林-巴利症候群中，腦脊髓液分析通常顯示蛋白質水平升高而白血球沒有顯著增加，這種發現稱為白蛋白細胞分離。然而，這種標誌性特徵可能在疾病的早期階段不存在，如果臨床懷疑仍然很高，則需要重複檢測。

主要市場促進因素

格林-巴利症候群發生率上升

主要市場挑戰

認知不足和誤診

主要市場趨勢

診斷技術的進步

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：COVID-19 對全球格林巴利症候群診斷市場的影響

第 5 章：全球格林巴利症候群診斷市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 透過檢查（腰椎穿刺、肌電圖、其他）
    • 依最終用途（醫院和診所、診斷實驗室、其他）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：北美格林巴利症候群診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 墨西哥
    • 加拿大

第 7 章：歐洲格林巴利症候群診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 德國
    • 英國
    • 義大利
    • 西班牙

第 8 章：亞太地區格林-巴利症候群診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 韓國
    • 日本
    • 澳洲

第 9 章：南美洲格林巴利症候群診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲格林-巴利症候群診斷市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 測試啟動（如果有）
  • 最新動態

第 13 章：全球格林巴利症候群診斷市場：SWOT 分析

第 14 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章：競爭格局

  • Cadwell Industries, Inc
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Medtronic plc
  • Bionen srl
  • Deymed Diagnostic sro
  • Neurosoft Ivanovo, Russia
  • Alpine Biomedicals Pvt Ltd.
  • EMS Handels Gesellschaft mbH
  • Rochester Electro-Medical, Inc.

第 16 章：策略建議

第17章 關於出版商,免責事項

簡介目錄
Product Code: 27713

Global Guillain-Barre Syndrome Diagnostics Market was valued at USD 150.95 Million in 2024 and is expected to reach USD 173.42 Million by 2030 with a CAGR of 5.12% during the forecast period. Guillain-Barre Syndrome (GBS) is a rare but serious neurological disorder in which the body's immune system mistakenly attacks the peripheral nervous system, leading to muscle weakness, numbness, and in severe cases, paralysis. Early and accurate diagnosis is critical for effective management and treatment, but the condition's variability and overlapping symptoms with other neurological disorders make its identification challenging.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 150.95 Million
Market Size 2030USD 173.42 Million
CAGR 2025-20302.30%
Fastest Growing SegmentLumbar Puncture
Largest MarketNorth America

The first step in diagnosing GBS involves a detailed clinical examination and patient history. Physicians assess the onset and progression of muscle weakness, typically starting in the lower limbs and ascending toward the upper body. Reflexes are often diminished or absent, a hallmark characteristic of GBS. Patients may also report sensory disturbances, such as tingling or pain, and autonomic dysfunction, including blood pressure fluctuations and abnormal heart rhythms. Since GBS is often triggered by a preceding infection, doctors inquire about recent illnesses such as respiratory infections or gastrointestinal disturbances.

Nerve conduction studies (NCS) and electromyography (EMG) are essential diagnostic tools for confirming GBS. NCS measures the speed and strength of electrical signals in the peripheral nerves. In GBS, these signals are slowed or blocked due to nerve demyelination or axonal damage. EMG, which assesses muscle response to nerve stimulation, can help distinguish GBS from other neuromuscular conditions. The results of these tests provide valuable insights into the subtype of GBS, such as acute inflammatory demyelinating polyneuropathy (AIDP) or acute motor axonal neuropathy (AMAN).

A lumbar puncture (spinal tap) is often performed to analyze cerebrospinal fluid (CSF), which surrounds the brain and spinal cord. In GBS, CSF analysis typically reveals elevated protein levels without a significant increase in white blood cells, a finding known as albuminocytological dissociation. However, this hallmark feature may not be present in the early stages of the disease, requiring repeated testing if clinical suspicion remains high.

Key Market Drivers

Rising Incidence of Guillain-Barre Syndrome

Guillain-Barre Syndrome (GBS) is an autoimmune disorder in which the body's immune system mistakenly attacks the peripheral nervous system, leading to muscle weakness, paralysis, and, in severe cases, respiratory failure. The global rise in the incidence of GBS has become a significant concern for healthcare providers, prompting increased demand for accurate and timely diagnostic solutions. The growing number of GBS cases worldwide, fueled by viral infections, vaccinations, and other autoimmune triggers, is a key driver of the expanding Guillain-Barre Syndrome diagnostics market. According to the National Organization for Rare Disorders (NORD), Guillain-Barre Syndrome (GBS) impacts approximately one to two individuals per 100,000 people annually.

One of the major factors contributing to the rising incidence of GBS is the increased prevalence of viral infections such as Zika virus, cytomegalovirus, and Epstein-Barr virus, which have been linked to the onset of the syndrome. Additionally, seasonal influenza and COVID-19 infections have also been associated with a higher risk of developing GBS. The correlation between these infections and GBS has intensified the need for early and precise diagnostic tools, including cerebrospinal fluid (CSF) analysis, electromyography (EMG), and nerve conduction studies (NCS), which are essential for confirming GBS and differentiating it from other neurological disorders.

Advancements in diagnostic technologies are further propelling market growth. Innovations in biomarker detection, molecular diagnostics, and imaging techniques have enhanced the ability to identify GBS in its early stages, leading to improved patient outcomes. Additionally, artificial intelligence (AI)-driven diagnostic solutions are being developed to enhance the accuracy and efficiency of GBS detection. These technological advancements are helping to meet the growing demand for rapid and reliable diagnostic procedures, further expanding the market.

Key Market Challenges

Limited Awareness and Misdiagnosis

One of the primary challenges in the GBS diagnostics market is the lack of awareness among healthcare providers and the general population. Guillain-Barre Syndrome presents with symptoms similar to other neurological disorders, such as multiple sclerosis and myasthenia gravis, leading to frequent misdiagnosis or delayed identification. This delay in diagnosis can significantly impact patient outcomes, as early intervention is critical in managing the condition effectively.

Key Market Trends

Technological Advancements in Diagnostics

One of the key trends shaping the GBS diagnostics market is the advancement in diagnostic technologies. Modern electrophysiological tests, such as NCS and EMG, are becoming more precise and efficient, aiding in the differentiation of GBS subtypes. Additionally, biomarker research has gained traction, with efforts focused on identifying specific autoantibodies and inflammatory markers that could improve the accuracy of GBS diagnosis. The integration of artificial intelligence (AI) and machine learning in medical imaging and electrophysiology has the potential to enhance diagnostic efficiency, reducing the time needed for clinical decision-making.

Key Market Players

  • Cadwell Industries, Inc
  • Natus Medical Incorporated
  • Nihon Kohden Corporation
  • Medtronic plc
  • Bionen s.r.l.
  • Deymed Diagnostic s.r.o.
  • Neurosoft Ivanovo, Russia
  • Alpine Biomedicals Pvt Ltd.
  • EMS Handels Gesellschaft m.b.H.
  • Rochester Electro-Medical, Inc.

Report Scope

In this report, the Global Guillain-Barre Syndrome Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Guillain-Barre Syndrome Diagnostics Market, By Test:

  • Lumbar Puncture
  • Electromyography
  • Others

Guillain-Barre Syndrome Diagnostics Market, By End use:

  • Hospitals And Clinics
  • Diagnostic Laboratories
  • Others

Guillain-Barre Syndrome Diagnostics Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Guillain-Barre Syndrome Diagnostics Market.

Available Customizations:

Global Guillain-Barre Syndrome Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Guillain-Barre Syndrome Diagnostics Market

5. Global Guillain-Barre Syndrome Diagnostics Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test (Lumbar Puncture, Electromyography, Others)
    • 5.2.2. By End Use (Hospitals And Clinics, Diagnostic Laboratories, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2024)
  • 5.3. Market Map

6. North America Guillain-Barre Syndrome Diagnostics Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test
    • 6.2.2. By End Use
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Guillain-Barre Syndrome Diagnostics Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test
        • 6.3.1.2.2. By End Use
    • 6.3.2. Mexico Guillain-Barre Syndrome Diagnostics Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test
        • 6.3.2.2.2. By End Use
    • 6.3.3. Canada Guillain-Barre Syndrome Diagnostics Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test
        • 6.3.3.2.2. By End Use

7. Europe Guillain-Barre Syndrome Diagnostics Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test
    • 7.2.2. By End Use
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test
        • 7.3.1.2.2. By End Use
    • 7.3.2. Germany Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test
        • 7.3.2.2.2. By End Use
    • 7.3.3. United Kingdom Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test
        • 7.3.3.2.2. By End Use
    • 7.3.4. Italy Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test
        • 7.3.4.2.2. By End Use
    • 7.3.5. Spain Guillain-Barre Syndrome Diagnostics Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test
        • 7.3.5.2.2. By End Use

8. Asia Pacific Guillain-Barre Syndrome Diagnostics Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test
    • 8.2.2. By End Use
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test
        • 8.3.1.2.2. By End Use
    • 8.3.2. India Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test
        • 8.3.2.2.2. By End Use
    • 8.3.3. South Korea Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test
        • 8.3.3.2.2. By End Use
    • 8.3.4. Japan Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test
        • 8.3.4.2.2. By End Use
    • 8.3.5. Australia Guillain-Barre Syndrome Diagnostics Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test
        • 8.3.5.2.2. By End Use

9. South America Guillain-Barre Syndrome Diagnostics Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test
    • 9.2.2. By End Use
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Guillain-Barre Syndrome Diagnostics Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test
        • 9.3.1.2.2. By End Use
    • 9.3.2. Argentina Guillain-Barre Syndrome Diagnostics Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test
        • 9.3.2.2.2. By End Use
    • 9.3.3. Colombia Guillain-Barre Syndrome Diagnostics Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test
        • 9.3.3.2.2. By End Use

10. Middle East and Africa Guillain-Barre Syndrome Diagnostics Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test
    • 10.2.2. By End Use
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Guillain-Barre Syndrome Diagnostics Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test
        • 10.3.1.2.2. By End Use
    • 10.3.2. Saudi Arabia Guillain-Barre Syndrome Diagnostics Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test
        • 10.3.2.2.2. By End Use
    • 10.3.3. UAE Guillain-Barre Syndrome Diagnostics Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test
        • 10.3.3.2.2. By End Use

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Test Launches (If Any)
  • 12.3. Recent Developments

13. Global Guillain-Barre Syndrome Diagnostics Market: SWOT Analysis

14. Porters Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. Competitive Landscape

  • 15.1. Cadwell Industries, Inc
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Natus Medical Incorporated
  • 15.3. Nihon Kohden Corporation
  • 15.4. Medtronic plc
  • 15.5. Bionen s.r.l.
  • 15.6. Deymed Diagnostic s.r.o.
  • 15.7. Neurosoft Ivanovo, Russia
  • 15.8. Alpine Biomedicals Pvt Ltd.
  • 15.9. EMS Handels Gesellschaft m.b.H.
  • 15.10. Rochester Electro-Medical, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer